Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Noteableon Aug 01, 2023 6:38pm
228 Views
Post# 35567845

ONCY's bought deal to support 2 Phase 3 studies

ONCY's bought deal to support 2 Phase 3 studies... upon the commencement of the Phase 3 study in metastatic breast cancer with pelareorep + paclitaxel a pre-negotiated payment of US$ 85 million will flow to ONCY as part of the deal with Adlai Nortye that gave AN exclusive rights to pelareorep in China and certain Chinese territories .


The announced US$15 million raise will give ONCY the firepower to initiate 2 Phase 3 studies in pancreatic and metastatic breast cancer.

Adlai Nortye has already received approval from the Chinese regulators to run a Phase 3 involving pelareorep and paclitaxel in mBC. 

A Phase 3 in mBC will give ONCY the second trial in ER+/Her2-  mBC that the FDA has sought to validate ONCY's first study that showed pelareorep + paclitaxel doubled patient survival nd which would accelerate the FDA's approval of pelareorep as a single agent in the treatment of this cancer that has an unmet medical treatment need.

The second Phase 3 study involves PanCan who intends to rapidly achieve approval for pelareorep in combination with atezolizumab + gemcitabine + chemotherapy for the treatment of early stage pancreatic cancer 
<< Previous
Bullboard Posts
Next >>